The immunobiology of malignant gliomas

Rosanna Nano, Mauro Ceroni

Research output: Contribution to journalArticle

Abstract

In spite of continuing advances in surgery, radiotherapy and chemotherapy, the last few decades have brought little improvement in the prognosis of malignant brain tumours. New immunotherapeutic strategies are being studied in numerous laboratories throughout the world in an effort to gather the further clinical and biological data needed in order to render these therapies effective and selective. The authors review recent advances in understanding of the immunobiology of brain tumours, in particular malignant gliomas. The biological basis of the interaction between nervous system cells and cancer cells is still an unresolved question and a constantly evolving area of research. Particular attention is paid to interleukin-2, one of the few effective cytokines used in the adjuvant treatment of some tumours. However, there is still a long way to go before these and other immunological approaches can be considered really applicable in the treatment of malignant gliomas.

Original languageEnglish
Pages (from-to)39-42
Number of pages4
JournalFunctional Neurology
Volume20
Issue number1
Publication statusPublished - Jan 2005

Fingerprint

Glioma
Brain Neoplasms
Nervous System
Interleukin-2
Neoplasms
Radiotherapy
Therapeutics
Cytokines
Drug Therapy
Research

Keywords

  • Astrocytic tumours
  • Cytokines
  • Immunobiology
  • Lymphocytes
  • Therapeutic strategies

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

The immunobiology of malignant gliomas. / Nano, Rosanna; Ceroni, Mauro.

In: Functional Neurology, Vol. 20, No. 1, 01.2005, p. 39-42.

Research output: Contribution to journalArticle

Nano, Rosanna ; Ceroni, Mauro. / The immunobiology of malignant gliomas. In: Functional Neurology. 2005 ; Vol. 20, No. 1. pp. 39-42.
@article{ece600fd9dc14282ab1f42336127a7da,
title = "The immunobiology of malignant gliomas",
abstract = "In spite of continuing advances in surgery, radiotherapy and chemotherapy, the last few decades have brought little improvement in the prognosis of malignant brain tumours. New immunotherapeutic strategies are being studied in numerous laboratories throughout the world in an effort to gather the further clinical and biological data needed in order to render these therapies effective and selective. The authors review recent advances in understanding of the immunobiology of brain tumours, in particular malignant gliomas. The biological basis of the interaction between nervous system cells and cancer cells is still an unresolved question and a constantly evolving area of research. Particular attention is paid to interleukin-2, one of the few effective cytokines used in the adjuvant treatment of some tumours. However, there is still a long way to go before these and other immunological approaches can be considered really applicable in the treatment of malignant gliomas.",
keywords = "Astrocytic tumours, Cytokines, Immunobiology, Lymphocytes, Therapeutic strategies",
author = "Rosanna Nano and Mauro Ceroni",
year = "2005",
month = "1",
language = "English",
volume = "20",
pages = "39--42",
journal = "Functional Neurology",
issn = "0393-5264",
publisher = "CIC Edizioni Internazionali s.r.l.",
number = "1",

}

TY - JOUR

T1 - The immunobiology of malignant gliomas

AU - Nano, Rosanna

AU - Ceroni, Mauro

PY - 2005/1

Y1 - 2005/1

N2 - In spite of continuing advances in surgery, radiotherapy and chemotherapy, the last few decades have brought little improvement in the prognosis of malignant brain tumours. New immunotherapeutic strategies are being studied in numerous laboratories throughout the world in an effort to gather the further clinical and biological data needed in order to render these therapies effective and selective. The authors review recent advances in understanding of the immunobiology of brain tumours, in particular malignant gliomas. The biological basis of the interaction between nervous system cells and cancer cells is still an unresolved question and a constantly evolving area of research. Particular attention is paid to interleukin-2, one of the few effective cytokines used in the adjuvant treatment of some tumours. However, there is still a long way to go before these and other immunological approaches can be considered really applicable in the treatment of malignant gliomas.

AB - In spite of continuing advances in surgery, radiotherapy and chemotherapy, the last few decades have brought little improvement in the prognosis of malignant brain tumours. New immunotherapeutic strategies are being studied in numerous laboratories throughout the world in an effort to gather the further clinical and biological data needed in order to render these therapies effective and selective. The authors review recent advances in understanding of the immunobiology of brain tumours, in particular malignant gliomas. The biological basis of the interaction between nervous system cells and cancer cells is still an unresolved question and a constantly evolving area of research. Particular attention is paid to interleukin-2, one of the few effective cytokines used in the adjuvant treatment of some tumours. However, there is still a long way to go before these and other immunological approaches can be considered really applicable in the treatment of malignant gliomas.

KW - Astrocytic tumours

KW - Cytokines

KW - Immunobiology

KW - Lymphocytes

KW - Therapeutic strategies

UR - http://www.scopus.com/inward/record.url?scp=19144362665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19144362665&partnerID=8YFLogxK

M3 - Article

C2 - 15948568

AN - SCOPUS:19144362665

VL - 20

SP - 39

EP - 42

JO - Functional Neurology

JF - Functional Neurology

SN - 0393-5264

IS - 1

ER -